Description:
The development of new cancer therapeutics is expensive, time-consuming, and only 7% of anti-cancer drugs in clinical trials become approved for clinical use. There is, therefore, a significant need for new cancer models to improve our understanding of cancer progression and for testing new therapeutics. This is especially true for the hardest to treat cancers. This session features innovative and novel models of some of the least understood and most difficult to treat cancers including ovarian cancer, glioblastoma, triple negative breast cancer, and pancreatic cancer.
Sponsor:
Engineering Fundamentals in Life Science
Co-chairs:
Kaitlin Fogg
Chemical, Biological & Environmental Engineering, Oregon State University, Corvallis, OR
Handan Acar
Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK
Abstract Submissions Closed
See more of this Group/Topical: Food, Pharmaceutical & Bioengineering Division